Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

U.S. Stem Cell Inc (USRM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 7,179
  • Shares Outstanding, K 381,882
  • Annual Sales, $ 5,520 K
  • Annual Income, $ -3,480 K
  • 36-Month Beta 5.91
  • Price/Sales 1.10
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/14/18
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0106 +77.36%
on 12/26/18
0.0230 -18.26%
on 01/03/19
+0.0058 (+44.62%)
since 12/21/18
3-Month
0.0106 +77.36%
on 12/26/18
0.0315 -40.32%
on 10/29/18
-0.0117 (-38.36%)
since 10/22/18
52-Week
0.0106 +77.36%
on 12/26/18
0.0880 -78.64%
on 04/09/18
-0.0222 (-54.15%)
since 01/22/18

Most Recent Stories

More News
USRM Chief Science Officer Featured on One Radio Network

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced its Chief Science Officer has...

USRM : 0.0198 (+5.32%)
USRM Chief Science Officer Featured on One Radio Network

SUNRISE, Fla. , Jan. 15, 2019 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions,...

USRM : 0.0198 (+5.32%)
Dr. Kristin Comella Featured on Robert Scott Bell Show

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced its Chief Science Officer, Dr....

USRM : 0.0198 (+5.32%)
USRM Posts 25% Nine Month Revenue Increase From 3Q 2017

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced third quarter results for this...

USRM : 0.0198 (+5.32%)
USRM Posts 25% Nine Month Revenue Increase From 3Q 2017

SUNRISE, Fla. , Nov. 7, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions,...

USRM : 0.0198 (+5.32%)
Adipose Stem Cells Demonstrate Effectiveness in Repairing Decubitus Ulcers

SUNRISE, Fla. , Oct. 9, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions,...

USRM : 0.0198 (+5.32%)
USRM Chief Science Officer Featured on YourVoice™ America

SUNRISE, Fla. , Oct. 1, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions,...

USRM : 0.0198 (+5.32%)
USRM Chief Science Officer Featured on YourVoice(TM) America

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced its Chief Science Officer, Dr....

USRM : 0.0198 (+5.32%)
Dr. Kristin Comella Joins Top Docs in Fix for Female Hormones Seminar

SUNRISE, Fla. , Sept. 26, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions,...

USRM : 0.0198 (+5.32%)
Dr. Kristin Comella Joins Top Docs in Fix for Female Hormones Seminar

U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced its Chief Science Officer, Dr....

USRM : 0.0198 (+5.32%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade USRM with:

Key Turning Points

2nd Resistance Point 0.0242
1st Resistance Point 0.0215
Last Price 0.0198
1st Support Level 0.0166
2nd Support Level 0.0144

See More

52-Week High 0.0880
Fibonacci 61.8% 0.0584
Fibonacci 50% 0.0493
Fibonacci 38.2% 0.0402
Last Price 0.0198
52-Week Low 0.0106

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar